Overall postoperative complications (within 30 days of operation) · women with gynaecological cancers
Enhanced recovery after surgery programme showed no clear difference in overall postoperative complications (within 30 days of operation) compared with traditional care (low certainty).
1 finding from 1 review
Mortality (within 30 days of discharge) · women with gynaecological cancers
It is very uncertain whether enhanced recovery after surgery programme changes mortality (within 30 days of discharge) compared with traditional care (very low certainty).
1 finding from 1 review
Patient readmissions · women with gynaecological cancers
Enhanced recovery after surgery programme may leads to lower readmission (within 30 days of operation) compared with traditional care (low certainty).
1 finding from 1 review
Duration of antifungal use (days) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Referral time (days)e · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Presentation time (days)f · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of neutropaenia (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Length of hospitalisation (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Duration of antimicrobial treatment (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Fever clearance time · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Duration of neutropaenia (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Length of hospitalisation (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Fever clearance time · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Intervention not reported
Time to PVR ≤ 50 mL (days) · women with stage Ia2 to IIa cervical cancer
The intervention showed no clear difference in time to PVR ≤ 50 mL (days) (low certainty).
1 finding from 1 review